Apellis Pharmaceuticals, Inc. announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.84 USD | -4.05% | +0.42% | -20.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.08% | 6.05B | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-14.82% | 15.36B | |
-8.82% | 11.95B | |
-16.29% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer